
The FDA Approves Powerful HIV Prevention Drug
HuffPost
But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.
The Food and Drug Administration on Wednesday approved a powerful new drug that provides almost complete protection against HIV infections.
The twice-yearly injection, known as lenacapavir, offers near-perfect protection against infection across broad populations and geographies, two clinical trials showed. It’s a promising development, but public health experts are concerned about how widely available the drug will be, considering President Donald Trump has enacted deep cuts to both global and domestic HIV programs since taking office in January.
“We’re on the precipice of now being able to deliver the greatest prevention option we’ve had in 44 years of this epidemic,” said Mitchell Warren, the executive director of AVAC, a global HIV prevention organization. “It’s as if that opportunity is being snatched out of our hands by the policies of the last five months.”
Trump froze all programming and services under PEPFAR, the U.S. government’s global health initiative to treat and prevent HIV and AIDS abroad.
Soon after that, the Trump administration decimated the nation’s domestic HIV prevention programs amid Robert F. Kennedy Jr.’s dramatic takeover of the Department of Health and Human Services. Kennedy quickly shut down several offices within HHS and the Centers for Disease Control and Prevention that had been dedicated to developing HIV prevention strategies and tracking new infections.













